Table 1 Sociodemographic, antipsychotic medications and baseline symptom scores in 40Hz-tACS and sham group.

From: Double-blind, randomized, placebo-controlled pilot clinical trial with gamma-band transcranial alternating current stimulation for the treatment of schizophrenia refractory auditory hallucinations

Measure

tACS (n = 16)

(mean ± sd)

Sham (n = 16)

(mean ± sd)

t/χ2

P value

Demographics

 Age(years)

45.38 ± 12.03

48.06 ± 11.38

−0.65

0.52

 Education (years)

11.06 ± 2.79

11.94 ± 2.74

−0.89

0.37

 Duration of schizophrenia (years)

19.94 ± 11.45

25.44 ± 11.01

−1.39

0.17

 Eqdose (mg)

467.19 ± 187.28

395.94 ± 217.24

0.99

0.32

 Gender (F/M)

9/7

9/7

0.00

1.00

 Family history (N/Y)

14/2

12/4

0.21

0.65

Matrimony

 Unmarried

7

7

  

 Married

5

1

  

 Divorce

4

8

  

 Clozapine(N/Y)

8/8

9/7

0.00

1.00

 APD (N/Y)

9/7

13/3

1.31

0.25

Baseline Measures

PANSS

 Hallucinations

6.00 ± 0.63

6.00 ± 0.73

0.00

1.00

 Total score

88.25 ± 15.25

88.81 ± 16.39

−0.10

0.92

 Positive Symptoms

25.19 ± 3.75

25.81 ± 3.80

−0.47

0.64

 Negative Symptoms

26.62 ± 7.04

24.62 ± 5.46

0.90

0.38

 General psychopathology

36.44 ± 7.47

38.38 ± 10.24

−0.61

0.55

PSYRATS

 Total Score

52.06 ± 8.14

49.56 ± 10.03

0.78

0.45

 Auditory hallucinations

33.94 ± 4.49

31.44 ± 6.51

1.26

0.21

 delusions

18.12 ± 4.62

18.12 ± 4.53

0.00

1.00